Articles
12 June 2009
Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
https://doi.org/10.4081/hmr.v3i3.557

New treatment options for elderly myeloma patients: the Italian experience

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
220
Views
278
Downloads

Authors

A Palumbo
support@pagepress.org
M Genuardi
S Bringhen
Multiple myeloma accounts for approximately 10% of hematologic malignancies, the frequency is constantly increasing due to aging of the general population.1,2 Recently, novel agents, such as thalidomide, bortezomib and lenalidomide have shown significant activity in multiple myeloma. Combinations of these agents with steroids, alkylating agents or anthracyclines have significantly improved response rate and progression- free survival (PFS). In elderly patients, older than 65 years, oral melphalan and prednisone (MP) has been combined with thalidomide or bortezomib significantly improving response rate and PFS.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



New treatment options for elderly myeloma patients: the Italian experience. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.557